Gyre Therapeutics (GYRE) AI Stock Analysis

• Market Cap: $658.49M
• Dividend Yield: N/A
• Average Volume (3M): 102.52K
• Price to Earnings (P/E): 444.8
• Beta (1Y): 1.93
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 579
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 90,826,775
• 10 Day Avg. Volume: 112,833
• 30 Day Avg. Volume: 102,519
• PEG Ratio: -0.78
• Price to Book (P/B): 16.26
• Price to Sales (P/S): 9.74
• P/FCF Ratio: -172.88
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 6.89
• Enterprise Value/Gross Profit: 4.96
• Enterprise Value/Ebitda: 17.79
• 1Y Price Target: $18.00
• Price Target Upside: 127.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $7.00 ▼(-11.62% Downside)

The overall stock score is primarily influenced by strong financial performance, particularly profitability and a solid balance sheet. However, significant cash flow management issues and bearish technical indicators weigh heavily on the score. Additionally, the stock appears overvalued based on its high P/E ratio, further impacting its attractiveness.

Positive Factors

Strong Profit Margins

High profit margins indicate efficient cost management and pricing power, which can sustain profitability even in competitive markets.

Robust Balance Sheet

Minimal leverage enhances financial stability and flexibility, allowing the company to invest in growth opportunities without excessive risk.

Pipeline Progress

Successful trial results and regulatory progress can lead to new product approvals, expanding market presence and driving future revenue growth.

Negative Factors

Cash Flow Challenges

Poor cash flow management can hinder operational flexibility and investment capacity, posing risks to long-term financial health.

Delayed Product Rollout

Delays in product rollout can impact revenue forecasts and market share, affecting the company's competitive position and growth trajectory.

Low Operating Cash Flow

Low operating cash flow relative to net income suggests inefficiencies in converting profits into cash, which may limit reinvestment potential.

Gyre Therapeutics Business Overview & Revenue Model

Company Description

Gyre Therapeutics (GYRE) is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company operates within the biotechnology sector, leveraging advanced drug discovery technologies to create treatments that address unmet medical needs in conditions such as Alzheimer's and Parkinson's disease. Gyre's core products include novel compounds that aim to modify disease progression and improve patient outcomes, supported by a strong pipeline of clinical and preclinical candidates.

How the Company Makes Money

Gyre Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model includes funding from government grants, partnerships with larger pharmaceutical firms, and potential royalties from successful product sales. Key revenue streams involve milestone payments from collaborations that focus on advancing drug candidates through clinical trials, licensing agreements for proprietary technologies, and eventually, sales of approved therapies. Significant partnerships with research institutions and pharmaceutical companies also contribute to Gyre's financial stability by providing access to additional resources and expertise.

Gyre Therapeutics Financial Statement Overview

Summary

Gyre Therapeutics demonstrates strong profitability with a high gross profit margin and improved net profit margin. The balance sheet is robust with low leverage and high return on equity. However, significant challenges in cash flow management, including a drastic decline in free cash flow growth, highlight the need for improved cash management.

Income Statement

Gyre Therapeutics shows a strong gross profit margin of 95.58% TTM, indicating efficient cost management. The net profit margin improved significantly to 28.79% TTM, reflecting enhanced profitability. Revenue growth is modest at 4.97% TTM, but the company has shown resilience with a positive trajectory from previous periods of decline. However, EBIT and EBITDA margins are relatively low, suggesting room for operational efficiency improvements.

Balance Sheet

The company's balance sheet is strong with a low debt-to-equity ratio of 0.015 TTM, indicating minimal leverage and financial stability. Return on equity is impressive at 62.70% TTM, showcasing effective use of equity to generate profits. The equity ratio is healthy, reflecting a solid capital structure. However, past periods showed negative equity, which could pose a risk if not managed carefully.

Cash Flow

Cash flow analysis reveals challenges, with a significant decline in free cash flow growth at -3765.82% TTM. The operating cash flow to net income ratio is low at 0.05 TTM, indicating potential cash flow issues. The negative free cash flow to net income ratio suggests the company is not generating sufficient cash from operations to cover its net income, highlighting a need for improved cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	107.27M	105.76M	113.45M	102.29M	7.34M	20.95M
Gross Profit	149.20M	101.87M	108.81M	97.50M	-42.00K	11.79M
EBITDA	41.55M	17.82M	20.33M	10.33M	-87.60M	-56.10M
Net Income	12.36M	12.09M	-92.93M	2.30M	-87.93M	-55.54M
Balance Sheet
Total Assets	159.38M	125.41M	116.54M	84.75M	55.66M	94.85M
Cash, Cash Equivalents and Short-Term Investments	40.40M	26.67M	33.51M	25.18M	46.85M	79.35M
Total Debt	1.17M	1.60M	409.00K	651.00K	2.38M	1.64M
Total Liabilities	21.97M	27.00M	102.59M	12.54M	14.57M	18.78M
Stockholders Equity	101.92M	63.32M	-15.83M	42.52M	41.09M	76.07M
Cash Flow
Free Cash Flow	2.90M	-5.96M	17.31M	-38.09M	-84.59M	-55.31M
Operating Cash Flow	3.88M	-3.64M	25.89M	-33.10M	-83.75M	-55.05M
Investing Cash Flow	-4.33M	-19.88M	-19.76M	55.43M	48.19M	9.66M
Financing Cash Flow	25.02M	2.10M	2.50M	-45.01M	49.55M	60.38M

Gyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GYRE, the sentiment is Positive. The current price of 7.92 is above the 20-day moving average (MA) of 7.90, above the 50-day MA of 7.72, and below the 200-day MA of 8.76, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 53.37 is Neutral, neither overbought nor oversold. The STOCH value of 35.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GYRE.

Gyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DAWN	50 Neutral	$999.03M	―	-30.16%	―	31.11%	-46.75%
GYRE	49 Neutral	$658.49M	444.79	8.06%	―	―	―
KALV	45 Neutral	$544.64M	―	-190.18%	―	―	-13.14%
TERN	45 Neutral	$1.62B	―	-35.02%	―	―	20.37%
TYRA	41 Neutral	$764.29M	-7.71	-34.75%	―	―	-17.01%
MBX	38 Underperform	$1.15B	―	-24.43%	―	―	―

Gyre Therapeutics Corporate Events

Gyre Therapeutics Reports Strong Q3 2025 Results

Gyre Therapeutics Inc., a biopharmaceutical company based in San Diego, focuses on developing and commercializing therapies for organ fibrosis, with a particular emphasis on liver fibrosis treatments in the United States and China.

Gyre Therapeutics Announces Positive Phase 3 Results

On September 10, 2025, Gyre Therapeutics released an updated corporate presentation highlighting its strategic initiatives and clinical advancements. The company announced positive Phase 3 results for Hydronidone in treating CHB-associated liver fibrosis, with significant improvements in fibrosis regression and inflammation. These developments underscore Gyre’s commitment to expanding its therapeutic pipeline and strengthening its market position in fibrosis treatments, potentially impacting stakeholders by enhancing its competitive edge and paving the way for future product launches.

The most recent analyst rating on (GYRE) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.

Gyre Therapeutics Appoints Dan Weng to Board

On August 18, 2025, Gyre Therapeutics appointed Dan Weng, M.D., as a Class II director to its Board of Directors. Dr. Weng, who has extensive experience in managing global clinical trials and has held leadership roles in various contract research organizations, is expected to bring strategic insight and regulatory expertise to Gyre as it expands its commercial reach and advances its multinational pipeline.

The most recent analyst rating on (GYRE) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.

Gyre Therapeutics Reports Q2 2025 Earnings and Strategic Updates

Gyre Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing fibrosis-first therapies for chronic diseases, with a strong presence in both the United States and the People’s Republic of China. In its latest earnings report, Gyre Therapeutics announced a net income of $1.6 million for the second quarter of 2025, with revenues reaching $26.8 million. The company reaffirmed its full-year revenue guidance of $118-128 million, highlighting its strategic focus on expanding its commercial portfolio and advancing its pipeline of fibrosis therapies.

Gyre Therapeutics Appoints Ping Zhang as Interim CEO

On August 5, 2025, Gyre Therapeutics appointed Ping Zhang as Interim CEO following the resignation of Dr. Han Ying, who transitioned to a scientific leadership role. The company reported a net income of $1.6 million for Q2 2025 and reaffirmed its full-year revenue guidance. Gyre is progressing with its pipeline, including a pivotal Phase 3 trial of Hydronidone for CHB-associated liver fibrosis and the launch of Etorel in the PRC. The leadership change is expected to strengthen Gyre’s global expansion and accelerate its delivery of transformative therapies.

The most recent analyst rating on (GYRE) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.